IS5351A - Ný efnasambönd - Google Patents

Ný efnasambönd

Info

Publication number
IS5351A
IS5351A IS5351A IS5351A IS5351A IS 5351 A IS5351 A IS 5351A IS 5351 A IS5351 A IS 5351A IS 5351 A IS5351 A IS 5351A IS 5351 A IS5351 A IS 5351A
Authority
IS
Iceland
Prior art keywords
pct
new compounds
sec
date
pub
Prior art date
Application number
IS5351A
Other languages
English (en)
Inventor
Hardern David
Springthorpe Brian
Original Assignee
Astra Pharmaceuticals Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astra Pharmaceuticals Ltd. filed Critical Astra Pharmaceuticals Ltd.
Publication of IS5351A publication Critical patent/IS5351A/is

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Use Of Switch Circuits For Exchanges And Methods Of Control Of Multiplex Exchanges (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
IS5351A 1997-07-22 2000-01-19 Ný efnasambönd IS5351A (is)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9702772A SE9702772D0 (sv) 1997-07-22 1997-07-22 Novel compounds
PCT/SE1998/001392 WO1999005142A1 (en) 1997-07-22 1998-07-15 Novel compounds

Publications (1)

Publication Number Publication Date
IS5351A true IS5351A (is) 2000-01-19

Family

ID=20407803

Family Applications (1)

Application Number Title Priority Date Filing Date
IS5351A IS5351A (is) 1997-07-22 2000-01-19 Ný efnasambönd

Country Status (21)

Country Link
US (1) US6156756A (is)
EP (1) EP0996620B1 (is)
JP (1) JP2001510841A (is)
KR (1) KR20010022082A (is)
CN (1) CN1271359A (is)
AT (1) ATE216389T1 (is)
AU (1) AU8370598A (is)
BR (1) BR9811022A (is)
CA (1) CA2296648A1 (is)
DE (1) DE69804964T2 (is)
EE (1) EE200000042A (is)
HU (1) HUP0100202A3 (is)
ID (1) ID24837A (is)
IL (1) IL134112A0 (is)
IS (1) IS5351A (is)
NO (1) NO20000311L (is)
PL (1) PL338518A1 (is)
SE (1) SE9702772D0 (is)
SK (1) SK188099A3 (is)
TR (1) TR200000151T2 (is)
WO (1) WO1999005142A1 (is)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9702773D0 (sv) * 1997-07-22 1997-07-22 Astra Pharma Prod Novel compounds
ID27127A (id) * 1998-02-17 2001-03-01 Astrazeneca Uk Ltd SENYAWA-SENYAWA TRIAZOLO (4,5-d) PIRIMIDINA YANG BARU
SE9802574D0 (sv) * 1998-07-17 1998-07-17 Astra Pharma Prod Novel compounds
TWI229674B (en) 1998-12-04 2005-03-21 Astra Pharma Prod Novel triazolo[4,5-d]pyrimidine compounds, pharmaceutical composition containing the same, their process for preparation and uses
SE9904128D0 (sv) * 1999-11-15 1999-11-15 Astra Pharma Prod Novel compounds
SE9904129D0 (sv) * 1999-11-15 1999-11-15 Astra Pharma Prod Novel compounds
US6867199B2 (en) 2000-08-21 2005-03-15 Inspire Pharmaceuticals, Inc. Dinucleoside polyphosphate compositions and their therapeutic use
US7749981B2 (en) 2003-10-21 2010-07-06 Inspire Pharmaceuticals, Inc. Drug-eluting stents coated with non-nucleotide P2Y12 receptor antagonist compound
ATE469157T1 (de) 2003-10-21 2010-06-15 Inspire Pharmaceuticals Inc Tetrahydrofuroä3,4-düdioxolverbindungen und zusammensetzungen und verfahren zur inhibierung der trombozytenaggregation
US7335648B2 (en) 2003-10-21 2008-02-26 Inspire Pharmaceuticals, Inc. Non-nucleotide composition and method for inhibiting platelet aggregation
US7504497B2 (en) 2003-10-21 2009-03-17 Inspire Pharmaceuticals, Inc. Orally bioavailable compounds and methods for inhibiting platelet aggregation
US7932376B2 (en) 2005-05-05 2011-04-26 Inspire Pharmaceuticals, Inc. Pyrimidine-based non-nucleotide composition and method for inhibiting platelet aggregation
US7566722B2 (en) 2006-10-31 2009-07-28 Janssen Pharmaceutica, N.V. Triazolopyrimidine derivatives as ADP P2Y12 receptor antagonists
WO2008054796A2 (en) 2006-10-31 2008-05-08 Janssen Pharmaceutica, N.V. Triazolopyrimidine derivatives as adp p2y12 receptor antagonists
TWI496776B (zh) * 2007-11-15 2015-08-21 Astrazeneca Ab 製備(3aR,4S,6R,6aS)-6-胺基-2,2-二甲基四氫-3aH-環戊并[d][1,3]二氧雜環戊烯-4-醇之純非對映異構性之二苯甲醯-L-酒石酸鹽之方法
WO2010043721A1 (en) 2008-10-17 2010-04-22 Oryzon Genomics, S.A. Oxidase inhibitors and their use
US8993808B2 (en) 2009-01-21 2015-03-31 Oryzon Genomics, S.A. Phenylcyclopropylamine derivatives and their medical use
WO2011017108A2 (en) 2009-07-27 2011-02-10 Auspex Pharmaceuticals, Inc. Cyclopropyl modulators of p2y12 receptor
RU2602814C2 (ru) 2009-09-25 2016-11-20 Оризон Дженомикс С.А. Лизинспецифические ингибиторы деметилазы-1 и их применение
WO2011042217A1 (en) 2009-10-09 2011-04-14 Oryzon Genomics S.A. Substituted heteroaryl- and aryl- cyclopropylamine acetamides and their use
WO2011101740A1 (en) * 2010-02-16 2011-08-25 Actavis Group Ptc Ehf Improved processes for preparing ticagrelor intermediate, 4,6-dichloro-5-nitro-2-(propylthio)pyrimidine
US9616058B2 (en) 2010-02-24 2017-04-11 Oryzon Genomics, S.A. Potent selective LSD1 inhibitors and dual LSD1/MAO-B inhibitors for antiviral use
WO2011106573A2 (en) 2010-02-24 2011-09-01 Oryzon Genomics, S.A. Lysine demethylase inhibitors for diseases and disorders associated with hepadnaviridae
PT2560947T (pt) 2010-04-19 2016-11-24 Oryzon Genomics Sa Inibidores da desmetilase específica de lisina 1 e seu uso
EP2598480B1 (en) 2010-07-29 2019-04-24 Oryzon Genomics, S.A. Cyclopropylamine derivatives useful as lsd1 inhibitors
DK2598482T3 (en) 2010-07-29 2018-06-14 Oryzon Genomics Sa ARYLCYCLOPROPYLAMINE-BASED DEMETHYLASE INHIBITORS OF LSD1 AND THEIR MEDICAL USE
US9061966B2 (en) 2010-10-08 2015-06-23 Oryzon Genomics S.A. Cyclopropylamine inhibitors of oxidases
WO2012063126A2 (en) 2010-11-09 2012-05-18 Actavis Group Ptc Ehf Improved processes for preparing pure (3ar,4s,6r,6as)-6-amino-2,2-dimethyltetrahdro-3ah-cyclopenta[d] [1,3]-dioxol-4-ol and its key starting material
WO2012072713A2 (en) 2010-11-30 2012-06-07 Oryzon Genomics, S.A. Lysine demethylase inhibitors for diseases and disorders associated with flaviviridae
JP2014501756A (ja) 2010-12-20 2014-01-23 アクタビス・グループ・ピーティーシー・イーエイチエフ トリアゾロ[4,5−d]ピリミジン誘導体及びその中間体の新規調整方法
EP3981395A1 (en) 2011-02-08 2022-04-13 Oryzon Genomics, S.A. Lysine demethylase inhibitors for myeloproliferative disorders
CZ2011229A3 (cs) 2011-04-19 2012-08-15 Zentiva, K.S. Opticky aktivní soli (3aR,4S,6R,6aS)-6-amino-2,2-dimethyltetrahydro-3aH-cyklopenta-[d][1,3]dioxol-4-olu a zpusob jejich prípravy
JP6023795B2 (ja) * 2011-05-13 2016-11-09 アストラゼネカ アクチボラグ ベンジル[(3aS,4R,6S,6aR)−6−ヒドロキシ−2,2−ジメチルテトラヒドロ−3aH−シクロペンタ[d][1,3]ジオキソル−4−イル]カルバメートの調製方法および該方法における中間体
AU2012270017A1 (en) 2011-06-15 2014-01-16 Actavis Group Ptc Ehf Improved process for preparing cyclopentylamine derivatives and intermediates thereof
CN102924457A (zh) * 2011-08-12 2013-02-13 上海恒瑞医药有限公司 三唑并嘧啶类衍生物、其制备方法及其用途
EP2768805B1 (en) 2011-10-20 2020-03-25 Oryzon Genomics, S.A. (hetero)aryl cyclopropylamine compounds as lsd1 inhibitors
CA2849564C (en) 2011-10-20 2020-10-20 Oryzon Genomics, S.A. (hetero)aryl cyclopropylamine compounds as lsd1 inhibitors
CN102659691B (zh) * 2012-05-23 2014-04-02 山东诚创医药技术开发有限公司 一种4,6-二氯-5-氨基-2-丙硫基嘧啶的制备方法
KR102406288B1 (ko) 2012-12-21 2022-06-13 길리애드 사이언시즈, 인코포레이티드 폴리시클릭-카르바모일피리돈 화합물 및 그의 제약 용도
WO2014206187A1 (zh) 2013-06-24 2014-12-31 苏州明锐医药科技有限公司 替卡格雷及其中间体的制备方法
NO2865735T3 (is) 2013-07-12 2018-07-21
ES2859102T3 (es) 2013-07-12 2021-10-01 Gilead Sciences Inc Compuestos de carbamoilpiridona policíclica y su uso para el tratamiento de infecciones por VIH
WO2015162630A1 (en) 2014-04-25 2015-10-29 Anlon Chemical Research Organization Novel processes for preparing triazolo [4,5-d]- pyrimidines, including ticagrelor, vianew intermediates and new route of synthesis.
NO2717902T3 (is) 2014-06-20 2018-06-23
TW201613936A (en) 2014-06-20 2016-04-16 Gilead Sciences Inc Crystalline forms of(2R,5S,13aR)-8-hydroxy-7,9-dioxo-n-(2,4,6-trifluorobenzyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazepine-10-carboxamide
TWI677489B (zh) 2014-06-20 2019-11-21 美商基利科學股份有限公司 多環型胺甲醯基吡啶酮化合物之合成
EP3600292A4 (en) 2017-03-30 2021-04-07 Corvus Pharmaceuticals, Inc. PROCESS FOR THE MANUFACTURING OF TRIAZOLE [4,5D] PYRAMIDINE DERIVATIVES AND INTERMEDIATES THEREOF
CN110831928A (zh) * 2017-07-18 2020-02-21 隆萨有限公司 氯化s-丙基-硫基巴比妥酸的制备方法
WO2020068583A1 (en) * 2018-09-27 2020-04-02 Corvus Pharmaceuticals, Inc. Processes for making triazolo [4,5d] pyramidine derivatives and intermediates thereof
CN111116592A (zh) * 2019-11-27 2020-05-08 杭州沧海帆医药科技有限公司 嘧啶并三氮唑类化合物及其医药用途
CN115710275B (zh) * 2022-11-21 2024-02-02 河南中医药大学 一种嘧啶-tcp类化合物、制备方法和医药用途

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4742064A (en) * 1985-09-10 1988-05-03 Regents Of The University Of Minnesota Antiviral carbocyclic analogs of xylofuranosylpurines
GB8826205D0 (en) * 1988-11-09 1988-12-14 Wellcome Found Heterocyclic compounds
HU221880B1 (hu) * 1995-07-11 2003-02-28 Astrazeneca Ab, Vérlemezke-aggregáció inhibitorok, ezeket tartalmazó gyógyszerkészítmények és előállításuk
AU5501598A (en) * 1996-12-20 1998-07-17 Astra Pharmaceuticals Limited Triazolo{4,5-(d)}pyrimidinyl derivatives and their use as medicaments

Also Published As

Publication number Publication date
IL134112A0 (en) 2001-07-24
DE69804964D1 (de) 2002-05-23
WO1999005142A1 (en) 1999-02-04
EP0996620B1 (en) 2002-04-17
SK188099A3 (en) 2000-08-14
HUP0100202A2 (hu) 2001-08-28
ID24837A (id) 2000-08-24
SE9702772D0 (sv) 1997-07-22
AU8370598A (en) 1999-02-16
CN1271359A (zh) 2000-10-25
ATE216389T1 (de) 2002-05-15
BR9811022A (pt) 2000-09-12
PL338518A1 (en) 2000-11-06
US6156756A (en) 2000-12-05
DE69804964T2 (de) 2002-11-07
CA2296648A1 (en) 1999-02-04
HUP0100202A3 (en) 2001-10-29
EE200000042A (et) 2000-10-16
EP0996620A1 (en) 2000-05-03
TR200000151T2 (tr) 2000-09-21
KR20010022082A (ko) 2001-03-15
NO20000311D0 (no) 2000-01-21
NO20000311L (no) 2000-03-21
JP2001510841A (ja) 2001-08-07

Similar Documents

Publication Publication Date Title
EE200000042A (et) Uued ühendid
TR200000197T2 (tr) Yeni bileşimler
MY121867A (en) Novel triazolo(4,5-d)pyrimidine compounds.
AU2002305143A1 (en) Pyrazolo'1,5-a!pyridine derivatives
EE9900465A (et) Uued ühendid
TR200001603T2 (tr) Yeni bileşikler
PT1093819E (pt) Compostos e composicoes para fornecimento de agentes activos
IL133825A0 (en) Substituted 6-phenylphenanthridines, medicaments containing same and use thereof
EE9900315A (et) Pürrolo[3,4-d]pürimidinooni derivaadid ja nende kasutamine ravimitena
TR200000152T2 (tr) Yeni bileşikler.
TR200002380T2 (tr) Yeni triazolo (4,5-d) pirimidin bileşikleri
DE69911785D1 (de) Triazolo[4,5-d]pyrimidin-verbindungen
HK1056361A1 (en) Novel compounds